GILD

Gilead Sciences, Inc. · Healthcare · Drug Manufacturers - General
$140.45
+1.42 (+1.02%)
Mkt Cap: 174.33B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield6.2%
Dividend YieldN/A
Market Cap174.33B
Volume6.45M
Recent News
PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
businesswire.com · 2026-04-14
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
zacks.com · 2026-04-14
Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing
businesswire.com · 2026-04-13
Altfest L J & Co. Inc. Sells 4,944 Shares of Gilead Sciences, Inc. $GILD
defenseworld.net · 2026-04-13
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
zacks.com · 2026-04-10
AHF Slams Gilead for Role in Florida AIDS Drug Crisis
businesswire.com · 2026-04-10

Unlock the Full Deep Scan

9 AI agents analyze GILD across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →